NCT03523312View on ClinicalTrials.gov

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Pancreatic Cancer
Interventions
RADIATION

Hypofractionated ablative IMRT (HFA-IMRT)

total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions

DRUG

capecitabine

Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11570

Memorial Sloan Kettering Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03523312 - Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter